Latigo Biotherapeutics Appoints Industry Veteran Timothy P. Walbert as Board Chair [Yahoo! Finance]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Yahoo! Finance
THOUSAND OAKS, Calif. Nov. 19, 2024 /PRNewswire/ -- Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target pain at its source, today announced the appointment of Timothy P. Walbert as chair of its board of directors. With three decades of experience in the biopharmaceutical industry, he brings extensive leadership and strategic expertise to Latigo. Mr. Walbert replaces Nancy Stagliano , Ph.D., who will continue to remain as a board member. Mr. Walbert most recently served as chairman, president, and chief executive officer (CEO) of Horizon Therapeutics, where he created and led the company through a transformative era that culminated in its acquisition by Amgen for $28.3 billion . Currently, he is a senior advisor at Amgen. "Tim is an exceptional leader with a wealth of experience in biopharma that will be instrumental as we advance our pipeline of potential best-in-class non-opioid Nav1.8 inhibitor
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform [Yahoo! Finance]Yahoo! Finance
- Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy PlatformBusiness Wire
- New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD [Yahoo! Finance]Yahoo! Finance
- Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook [Yahoo! Finance]Yahoo! Finance
- Takeda Announces Strong First Half FY2024 Results and Raises Full Year OutlookBusiness Wire
TAK
Sec Filings
- 10/31/24 - Form 6-K
- 10/31/24 - Form 6-K
- 10/31/24 - Form 6-K
- TAK's page on the SEC website